Get the Stockscreener App
1.071
3.07%
-0.039
Cel-Sci Corp. stock is traded at $1.071, with a volume of 123.37K.
It is down -3.07% in the last 24 hours and down -30.14% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$1.11
Open:
$1.11
24h Volume:
123.37K
Relative Volume:
0.30
Market Cap:
$18.87M
Revenue:
-
Net Income/Loss:
$-22.70M
P/E Ratio:
-0.3078
EPS:
-3.4798
Net Cash Flow:
$-16.66M
1W Performance:
+6.52%
1M Performance:
-30.14%
6M Performance:
-79.27%
1Y Performance:
-55.17%
1-Day Range:
$1.075
$1.12
1-Week Range:
$0.96
$1.16
52-Week Range:
$0.89
$13.48
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
1.0796 | 19.40M | 0 | -22.70M | -16.66M | -3.4798 |
VRTX
Vertex Pharmaceuticals Inc
|
495.64 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.10 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
895.42 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.88 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
185.47 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
Why Did CEL-SCI Stock Plunge After Its Latest Offering - Kavout | AI
CVM: CEL-SCI Partners with Saudi Amarox for Multikine Launch - GuruFocus
CEL-SCI signs distribution deal with Saudi Amarox for Multikine - Investing.com
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care - The Joplin Globe
CEL-SCI Corp (CVM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CEL-SCI Corp (CVM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CVM stock sinks in pre-market trading after announcing second equity raise for its cancer drug in just over a month - MSN
CEL-SCI Corp (CVM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CEL-SCI Corp (CVM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CEL-SCI Corp (CVM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CEL-SCI Corp (CVM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BRIEF-CEL-SCI Announces Closing Of Offering - Dailyhunt
CEL-SCI Corp (CVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CEL-SCI Corp (CVM) Institutional Confidence - TradingKey
CEL-SCI Corp (CVM) Valuation: PE, PB & Fair Value Analysis - TradingKey
CEL-SCI Corporation Announces $2.5 Million Stock Offering to Advance Multikine Cancer Immunotherapy 1 - Minichart
CEL-SCI closes $2.5M stock offering at $1 per share By Investing.com - Investing.com South Africa
CEL-SCI (CVM) Advances Multikine for Head and Neck Cancer - GuruFocus
CEL-SCI Completes $2.5M Stock Offering at $1.00, Engages ThinkEquity as Placement Agent - TradingView
CEL-SCI (NYSE American: CVM) prices $2.5M best-efforts stock offering - Stock Titan
CEL-SCI closes $2.5M stock offering at $1 per share - Investing.com
CEL-SCI Announces Closing of Offering - Yahoo Finance
CEL-SCI to begin confirmatory study for head and neck cancer drug - Investing.com
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy - Yahoo Finance
[424B5] CEL SCI CORP Prospectus Supplement (Debt Securities) - Stock Titan
CEL-SCI Corporation (CVM) Prices Public Offering, Shares Drop in Premarket - GuruFocus
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month - Mena FN
CEL-SCI stock sale prices $2.5M to fund Multikine work - Stock Titan
CEL-SCI Corporation Announces Pricing of Offering - Yahoo Finance
CVM: CEL-SCI Partners with Saudi Amarox for Strategic Agreement - GuruFocus
CEL-SCI to formalize Saudi Arabia distribution agreement - Investing.com
Saudi cancer immunotherapy push brings CEL-SCI Multikine deal - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market SessionAditxt (NASDAQ:ADTX), Atossa Therapeutics - Benzinga
Cel-Sci Stock Slides 5.43% as Key Support Test LoomsBullish Pattern Stocks - newsline.com
CVM Technical Analysis | Trend, Signals & Chart Patterns | CEL-SCI CORP (NYSEARCA:CVM) - ChartMill
Cel-Sci (CVM) Holds Near Support as Biotech Stock Posts Modest GainChaikin Flow - newsline.com
CVM - Finviz
[RW] CEL SCI CORP SEC Filing - Stock Titan
CVM: CEL-SCI Advances Multikine Toward Regulatory Approval - GuruFocus
Cel Sci CEO Geert Kersten’s trust buys $360,000 in common stock By Investing.com - Investing.com South Africa
Cel Sci CEO Geert Kersten’s trust buys $360,000 in common stock - Investing.com Australia
Cel Sci Insider Bought Shares Worth $360,000, According to a Recent SEC Filing - marketscreener.com
CEL-SCI (NYSE: CVM) trust buys 300K restricted shares at $1.20 - Stock Titan
CEL-SCI adds Saudi partner, U.S. trial for head and neck cancer drug - Stock Titan
Cel-Sci: Fiscal Q2 Earnings Snapshot - cbs19news.com
CEL SCI CORP 1H 2026: Net loss $(10.94M), Diluted EPS $(1.35) — 10-Q Summary - TradingView
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 - marketscreener.com
CEL-SCI (NYSE: CVM) reports $10.9M loss and just $1.9M in cash - Stock Titan
CEL-SCI Partners with Amarox for Multikine Cancer Immunotherapy Commercialization in Saudi Arabia and GCC Region 12 - minichart.com.sg
CVM SEC FilingsCEL-SCI Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):